Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Gemcitabine in hematologic malignancies
Autore:
Nabhan, C; Krett, N; Gandhi, V; Rosen, S;
Indirizzi:
Northwestern Univ, Sch Med, Div Hematol Oncol, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA Northwestern Univ Chicago IL USA 60611 ns Canc Ctr, Chicago, IL 60611 USA Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA Univ Texas Houston TX USA 77030 ept Expt Therapeut, Houston, TX 77030 USA
Titolo Testata:
CURRENT OPINION IN ONCOLOGY
fascicolo: 6, volume: 13, anno: 2001,
pagine: 514 - 521
SICI:
1040-8746(200111)13:6<514:GIHM>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
CHRONIC LYMPHOCYTIC-LEUKEMIA; NON-HODGKINS-LYMPHOMA; BONE-MARROW TRANSPLANTATION; MECHANISM-BASED INHIBITORS; HUMAN DEOXYCYTIDINE KINASE; 2',2'-DIFLUORODEOXYCYTIDINE GEMCITABINE; PHASE-I; RIBONUCLEOTIDE REDUCTASE; NUCLEOSIDE TRANSPORTERS; CELLULAR PHARMACOLOGY;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
64
Recensione:
Indirizzi per estratti:
Indirizzo: Nabhan, C Northwestern Univ, Sch Med, Div Hematol Oncol, Robert H Lurie Comprehens Canc Ctr, 676 N St Clair St,Suite 850, Chicago, IL 60611 USA Northwestern Univ 676 N St Clair St,Suite 850 Chicago IL USA 60611
Citazione:
C. Nabhan et al., "Gemcitabine in hematologic malignancies", CURR OPIN O, 13(6), 2001, pp. 514-521

Abstract

Gemcitabine is a pyrimidine analogue that showed significant activity in solid malignancies. Gemcitabine acts by inhibiting DNA synthesis through chain termination and ribonucleotide reductase inhibition. During initial phase I and II studies, gemcitabine had a low toxicity profile and was well tolerated as a single agent and in combination therapy. Recently, there has been more interest in studying the activity of gemcitabine in hematologic malignancies. Gemcitabine demonstrated good activity in refractory Hodgkin disease patients, non-Hodgkin lymphoma, cutaneous T-cell lymphoma, and acute leukemias. There is a preponderance of evidence on the activity of gemcitabine in vitro in myeloma and leukemic cell lines. The activity of gemcitabinein these disorders will pave the way for incorporating this agent into theearly phases of therapy. Curr Opin Oncol 2001, 13:514-521 (C) 2001 Lippincott Williams & Wilkins, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 18:36:07